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Glioblastomas (GBMs), the most common primary
brain tumor in adults, are characterized by resistance
to chemotherapy and radiotherapy. One of the defin-
ing characteristics of GBM is an abundant and aber-
rant vasculature. The processes of vascular co-option,
angiogenesis, and vasculogenesis in gliomas have
been extensively described. Recently, however, it has
become clear that these three processes are not the
only mechanisms by which neovascularization oc-
curs in gliomas. Furthermore, it seems that these pro-
cesses interact extensively, with potential overlap
among them. At least five mechanisms by which glio-
mas achieve neovascularization have been described:
vascular co-option, angiogenesis, vasculogenesis, vas-
cular mimicry, and (the most recently described) glio-
blastoma-endothelial cell transdifferentiation. We re-
view these mechanisms in glioma neovascularization,
with a particular emphasis on the roles of hypoxia
and glioma stem cells in each process. Although some
of these processes are well established, others have
been identified only recently and will need to be fur-
ther investigated for complete validation. We also re-
view strategies to target glioma neovascularization
and the development of resistance to these therapeu-
tic strategies. Finally, we describe how these complex
processes interlink and overlap. A thorough under-
standing of the contributing molecular processes that
control the five modalities reviewed here should
help resolve the treatment resistance that character-
izes GBMs. (Am J Pathol 2012, 181:1126–1141; http://dx.
doi.org/10.1016/j.ajpath.2012.06.030)
Glioblastomas (GBMs) are the most common and ag-
gressive primary brain tumors in adults, with a median
survival of only 14 months despite the best available
treatments. GBMs are characterized by their resistance
to radiotherapy and chemotherapy, as well as their abun-
dant and aberrant vasculature. Neovascularization has
1126long been implicated as a salient feature of glioma pro-
gression. In fact, high-grade gliomas are among the most
vascular of all solid tumors, and vascular proliferation is a
pathological hallmark of GBMs.1 Tumor progression and
resistance to both radiotherapy and chemotherapy lead
to unfavorable clinical outcomes in glioma patients and
are associated with the hypoxic tumor microenvironment
known to exist within GBMs. Also contributing to resis-
tance to traditional therapeutics are glioma stem cells
(GSCs), which contain tumor-initiating functions and are
thought to be responsible for replenishing and sustaining
the glioma mass and promoting resistance to traditional
cancer therapies. An increasing body of experimental
evidence suggests that hypoxia and the hypoxia-induc-
ible factors (HIFs) play a critical role in maintaining the
stem-like fraction in gliomas by creating a microenviron-
ment that provides the essential cellular interactions and
environmental signals needed to prevent GSC differenti-
ation and to support their survival and self-renewal.2 Al-
though hypoxia is a well-known driver of neovascularization,
there is also evidence demonstrating that non-hypoxia-
driven mechanisms exist, including p53 and hypoxia-inde-
pendent vascular endothelial growth factor (VEGF)-medi-
ated pathways.
Glioma cells are able to sense and adapt to hypoxic
environments. HIF-1 is a heterodimeric nuclear transcrip-
tion factor3 that consists of two subunits, HIF-1 and
HIF-1. The HIF-1 subunit determines HIF-1 activity in
response to changes in local O2 levels. Under normoxic
conditions, the  subunit is rapidly degraded; under hy-
poxic conditions, however, this subunit remains intact
and binds to the constitutively expressed  subunit to
form HIF-1 in the cell nucleus, where it induces expres-
sion of many genes under the regulation of hypoxia re-
sponse elements. This process triggers the up-regulation
of multiple proangiogenic factors, the most studied and
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AJP October 2012, Vol. 181, No. 4prominent of which is VEGF. The resulting migration and
proliferation of endothelial cells are key events in the
angiogenic cascade.
Most studies have focused on the HIF-1 subunit, and
less is known about the role of HIF-2 in tumor progres-
sion. Several studies have shown that HIF-2 may be in-
volved in maintenance of GSCs. Both HIF-1 and HIF-2
are necessary for GSC maintenance. Furthermore, over-
expression of HIF-2 promotes a cancer stem-cell like
phenotype in preclinical models of GBM.4
Originally described simply as capillary sprouting from
pre-existing host tissue capillaries (ie, angiogenesis), the
process by which solid growing tumors generate an in-
creasing blood supply to meet their ever-increasing
nutrient and oxygen demand is now recognized as a
highly complex spectrum of events. At least five distinct
mechanisms of neovascularization in GBMs have been
identified: i) vascular co-option, ii) angiogenesis, iii) vas-
culogenesis, iv) vascular mimicry, and v) glioblastoma-
endothelial cell transdifferentiation. These mechanisms
are not independent of one another, but rather are inter-
linked and are controlled, at least in part, by similar pro-
cesses. Here, we review the evidence for and potential
molecular mechanisms of each of these processes and
discuss the experimental data for the roles of hypoxia
and stem cells in each of the five mechanisms. In addi-
tion, we review the rationale for the targeting of neovas-
cularization in gliomas (eg, antiangiogenic therapeutic
Figure 1. Vascular co-option.A: Temporally, vascular co-option is the first proce
cells into cuffs around normal microvessels (inset). Vascular co-option has been
of tumor cells in a sectioned human GBM specimen stained with H&E show vascular c
(bottom).strategies) and discuss the potential molecular mecha-
nisms that could explain escape from antiangiogenic
therapy. Finally, we describe how these complex mech-
anisms of vascularization might be interlinked. Although
we focus our review on neovascularization in gliomas,
there is evidence that many of these processes occur in
a broad range of malignancies.
Our objective here is to provide a thorough and com-
prehensive review of the mechanisms of glioma-associ-
ated neovascularization. We discuss processes that have
now become widely accepted by the scientific commu-
nity, such as vascular co-option, angiogenesis, and vas-
culogenesis. We also describe vascular mimicry and
transdifferentiation, processes that are only beginning to
be explored. Because they have been identified only
rather recently, the vascular mimicry and transdifferentia-
tion processes will require confirmation and validation
before they can be widely accepted. Furthermore, the
contribution of these two mechanisms to the process of
neovascularization on a whole-tumor scale may vary con-
siderably among tumor types and for now remains largely
unknown.
Vascular Co-Option
Temporally, vascular co-option is the first mechanism by
which gliomas achieve their vasculature (Figure 1). This
ich gliomas attain a vascular supply. The process involves organization of tumor
precede angiogenesis in tumor models by up to 4 weeks. B: Photomicrographsss bywh
shown too-option as classic perivascular cuffs. Original magnification: 50 (top); 200
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around normal microvessels. Holash et al5 were the first
to definitively demonstrate vessel co-option, using a rat
C6 glioma model. Early tumors were well vascularized
through vessel co-option, and it was not until approxi-
mately 4 weeks after implantation that, after vascular
regression, a robust angiogenic response was seen at
the viable tumor periphery. In the interim, the majority of
tumor vasculature was co-opted from normal brain vas-
culature. Co-opted vessels have been shown to express
angiopoietin-2 (ANG-2).5,6
The angiopoietins constitute a family of factors that
bind competitively on TIE-2. ANG-2 functions mainly as
an antagonist of ANG-1, but both pro- and antiangiogenic
functions have been described for both ANG-1 and
ANG-2. Although the situation is more complex, it is
thought that ANG-1 acts predominantly in pericyte re-
cruitment and maintenance of vessel integrity and that
up-regulation of ANG-2 expression leads to vessel de-
stabilization. At this stage, and in the presence of VEGF,
angiogenic vessel sprouting occurs. In the absence of
VEGF, however, ANG-2 promotes endothelial cell apop-
tosis and vessel regression.5,7
A temporal study of experimental glioma vasculariza-
tion identified vascular co-option as an initial step of a
cascade of events in implanted murine GL261 gliomas.6
As early as 1 week after glioma cell implantation, vascular
co-option was observed, with endothelial cell apoptosis
appearing by week 3, resulting in vascular regression
and regions of necrosis followed by angiogenesis. Invo-
lution of co-opted vessels resulted in tumor hypoxia, up-
regulation of proangiogenic factors, and a shift toward an
angiogenic phenotype. Rong et al8 reviewed pseudop-
alisading necrosis in GBM and described a similar se-
quence of events in human GBM.
Using in vivo multiphoton laser scanning microscopy
and the same GL261 murine glioma cell line, Winkler et
al9 described the invading potential of glioma cells when
in close contact with brain microvessels. At the invasive
border of the main tumor, vascularization occurred via
co-option of pre-existing brain vessels, rather than by
angiogenesis.
Possible molecular links between hypoxia and vascu-
lar co-option include the up-regulation of ANG-2 by hyp-
oxia through HIF-1–dependent mechanisms and the
presence of a HIF-1 binding hypoxia response element
location identified in the first intron of the ANG-2 gene
(ANGPT2).10 In addition, it has been shown that condi-
tioned medium collected from neoplastic cells exposed
to hypoxia promotes vascular co-option.11
Montana and Sontheimer12 recently described a po-
tential role for bradykinin in chemotaxis during vascular
co-option in primary brain tumors. In glioma biopsy spec-
imens, they demonstrated increased expression of bra-
dykinin receptors in regions of tumor, with the highest
levels in perivascular regions. Using in vitro assays, they
also demonstrated increased glioma cell motility and mi-
gration/invasion in both Transwell and brain slice invasion
assays in response to bradykinin, which was mediated by
bradykinin-induced Ca2 oscillations.Angiogenesis
Vascular co-option is followed by the development of new
vessels from pre-existing ones (Figure 2), a process
known as angiogenesis. This mechanism is integral to
both physiological and pathological processes. Angio-
genesis was described in GBM as early as 1976, when
Brem13 observed intense neovascularization in rabbit
corneas transplanted with GBMs, suggesting an in vivo
production of a “vasoformative substance.”
A detailed and comprehensive description of the mo-
lecular and cellular mechanisms and biology of angio-
genesis is beyond the scope of this review. Briefly, glio-
ma-associated sprouting angiogenesis begins with an
angiopoietin-mediated breakdown of existing vessels. Af-
ter vascular co-option, persistent up-regulation of ANG-2
and TIE-2 in endothelial and tumor cells promotes dis-
ruption of endothelial and perivascular cell junctions, re-
sulting in vessel disruption.5,7,14 A key early event is the
proteolysis of the basement membrane and extracellular
matrix due to the activity of matrix metalloproteinases
(MMPs). In the presence of ANG-2, VEGF promotes mi-
gration and proliferation of endothelial cells and stimu-
lates sprouting of new blood vessels. Acquisition of the
tip and stalk phenotypes among endothelial cells ex-
posed to proangiogenic stimuli involves the delta-like 4
(DLL-4)/Notch pathway.15 Recently, ephrin-B2 has been
shown to regulate VEGF-induced endothelial tip cell
guidance during angiogenesis, similar to its role in axonal
guidance.16
The final stages of angiogenesis involve capillary mor-
phogenesis, mediated largely by integrins 31 and v3,
as well as by CD44.17 Activated endothelial cells secrete
platelet-derived growth factor (PDGF), which recruits
pericytes to the newly formed vessel,18 aided by the
ANG/TIE pathway. Negative feedback by endogenous
antiangiogenic factors, as well as accumulation of extra-
cellular matrix, may modulate the process of vascular
modeling.19 A role for DLL-4/Notch in differentiation of
endothelial cells during the final stages of angiogenesis
has also been described,20,21 and inhibition of that path-
way has been proposed as a therapeutic target. Although
intussusception, which does not require the steps de-
scribed above, has been observed as a mechanism of
angiogenesis in other tumor types, it has not been ob-
served in glioma angiogenesis.
The end result of the neoplastic angiogenic process is
a characteristically abnormal vascular network, with di-
lated and tortuous vessels and abnormal branching and
arteriovenous shunts, which can also lead to abnormal
perfusion. GBMs in particular have immature vasculature,
with excessive leakiness, that can contribute to the
breakdown of the blood-brain barrier. In addition to phys-
ical disruption of existing vessels by lifting and displace-
ment of astrocytic foot processes by glioma cells,6 induc-
tion of leakiness by VEGF and vesiculovacuolar
organelles22 contribute to an abnormal blood-brain bar-
rier in the setting of glioma. The permeability of newly
formed vascular channels is increased, compared with
that of mature capillaries. Normal capillaries of the brain
maintain the integrity of the blood-brain barrier, but the
) to high
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are structurally altered and have increased capillary per-
meability, in part due to lack of a basal lamina (resulting
from persistent angiogenic stimuli leading to incomplete
maturation).
Several key pathways have been identified in the pro-
cess of glioma-associated angiogenesis, including eryth-
ropoietin and its receptor, DLL4 and its receptor Notch,
macrophage migration inhibitory factor (MIF), neuropi-
lin-2 (NRP2), placental growth factor (PlGF), and basic
fibroblast growth factor (bFGF), among others. The most
studied and best characterized factor is VEGF, which is
discussed in more detail below.
Hypoxia-Induced Glioma Angiogenesis
Hypoxia has long been known as a major stimulator of
angiogenesis in GBMs.3,23 The extensive list of angio-
genic factors (many of which are up-regulated by hyp-
oxia) and the various mechanisms of angiogenesis in
gliomas have been described in detail previously and
have been reviewed by Fischer et al.24 In particular,
VEGF, which is up-regulated by hypoxia, stimulates vas-
cularization during embryogenesis and in neoplastic tis-
sues. The VEGF family consists of five members: VEGF-A
Figure 2. Angiogenesis. A: Angiogenesis follows vascular co-option during
from pre-existing ones. Hypoxic pseudopalisading glioma cells around necr
balance toward a proangiogenic phenotype, inducing sprouting from pre-exis
described. B: Photomicrographs of a sectioned human GBM specimen stain
poorly vascularized regions with little angiogenesis (upper left in each panel
right in each panel). Original magnification: 20 (top); 100 (bottom).(referred to here simply as VEGF), VEGF-B, VEGF-C,VEGF-D, and placental growth factor (PlGF). VEGF exerts
its effects on the vascular endothelium through binding to
several high-affinity receptors, including VEGFR-1 (also
known as FLT-1) and VEGFR-2 (also known as FLK-1 and
KDR). The expression of VEGF and VEGFR correlates
with the grade of diffuse astrocytomas, is crucial for gli-
oma growth, and displays a temporal and spatial corre-
lation with the angiogenesis seen in human gliomas.25
Hypoxia induces HIF-1 expression in GBMs and is the
main molecular basis for the activation of VEGF gene
transcription, leading to angiogenesis. The expression
level of HIF-1 and VEGF in both human and murine
gliomas is intense around areas of necrosis in pseu-
dopalisading tumor cells,23,26 suggesting that this pat-
tern of HIF-1 and VEGF expression is modulated by
tumor oxygenation.
Abundant experimental evidence suggests that the
C-X-C chemokine receptor type 4/stromal-derived fac-
tor-1 (CXCR4/SDF-1) pathway is also a crucial com-
ponent of neovascularization in gliomas.27 CXCR4 is nor-
mally expressed at low levels in resting endothelial cells,
but is increased in response to VEGF stimulation.27
SDF-1 is a ligand of the chemokine receptor CXCR4.
Like VEGF, CXCR4 and SDF-1 are up-regulated by hyp-
oxia, as are several other molecules that play a critical
asculature development and is defined as the development of new vessels
et) release proangiogenic factors. This results in the shift of the angiogenic
sels. Hypoxia-independent mechanisms driving angiogenesis have also been
tenascin-C shows sprouting angiogenesis. Note the gradient from relatively
ly vascularized regions with hyperplastic vessels around necrosis (N) (lowertumor v
osis (ins
ting ves
ed forrole in the angiogenic cascade (eg, MMPs). Knockout
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SDF-1 are required for normal embryonic development
of the nervous system; importantly, CXCR4 is required for
vascularization of the gastrointestinal tract. The angio-
genic effects of SDF-1 have been shown both in vitro
and in vivo.28 SDF-1 acts as a chemoattractant for en-
dothelial cells and induces endothelial cell proliferation in
vitro, and promotes capillary sprouting and branching in
vivo. SDF-1 expression by gliomas and vascular endo-
thelial cells has been correlated with survival of endothe-
lial cells,29 whereas CXCR4 expression has been shown
to promote high levels of VEGF production by human
astrocytic glioma cells.30
Hypoxia-Independent Glioma Angiogenesis
Although hypoxia has been shown to play a critical role in
glioma angiogenesis, some experimental evidence also
indicates the existence of hypoxia-independent mecha-
nisms. Vascular proliferation can occur near the leading/
invading edge of GBM, often remote from the central
necrotic and hypoxic core of the tumor.
For example, using fresh-frozen human tissue, Jubb
et al31 showed in several tumor types that VEGF-A was
up-regulated in the absence of markers of hypoxia. Sim-
ilarly, Arany et al32 demonstrated induction of VEGF by
peroxisome-proliferator-activated receptor- coactiva-
tor-1 (PGC-1-) independently of HIF-1 through the es-
trogen-related receptor  (ERR-). Hypoxia-independent
mechanisms of HIF-1 stabilization have also been de-
scribed. For example, several genetic mutations (in-
cluding mutated genes encoding PDGFR, EGFR, p53,
Figure 3. Vasculogenesis. A: Vasculogenesis involves the mobilization, differe
genesis is induced largely by hypoxia-mediated release of various factors, the m
cells are not only incorporated into the neovasculature, but also can enter the tu
is used in our laboratory to study vasculogenesis in GL261 gliomas. When bone m
wild-type mouse, marrow-derived cells will express the Y chromosome and ma
tochemistry, and flow cytometry. These marrow transplant mice can be implanted intracran
transplanted BMDCs from the male donor to the endothelium and/or intratumoral cellular mRB1, VHL, and PTEN) have been shown to result in
HIF-1 stabilization3,23,33–35 resulting in increased an-
giogenesis due to the up-regulation of angiogenic fac-
tors. Some of these genetic mutations have been im-
plicated in gliomas.
Role of Glioma Stem Cells in Angiogenesis
Some experimental evidence suggests that GSCs play a
critical role in tumor progression, at least in part, through
their promotion of angiogenesis.36 Both VEGF and
SDF-1 have been shown to be important angiogenic
factors released by GSCs.36,37 This conception is
thought to be valid because GSCs thrive under hypoxic
conditions, proliferate, enhance the original tumor mass,
and express distinctly high levels of VEGF. Furthermore,
tumors with a high GSC content are highly angiogenic.36
Vasculogenesis
A third mechanism of tumor neovascularization, vasculo-
genesis, involves differentiation of circulating bone mar-
row-derived cells (BMDCs) known as endothelial progen-
itor cells (EPCs) (Figure 3A). Previous animal studies of
tumor-associated vasculogenesis produced discordant
findings. Although some studies have shown a significant
role for vasculogenesis in tumor neovessel formation,38
others have not,39 and it is likely that the relative contri-
bution of vasculogenesis to tumor neovascularization de-
pends on the specific tumor type. Supporting a role for
vasculogenesis in glioma neovascularization is the ob-
, and recruitment of BMDCs (blue). Similar to the angiogenic switch, vasculo-
ied of which are involved in the SDF-1/CXCR4 pathway. Circulating precursor
become tumor-associated macrophages (inset). B: A transgenic murine model
ells from a donor male transgenic mouse are transplanted into a recipient female
rived EPCs will express GFP detectable by fluorescence microscopy, immunohis-
ntiation
ost stud
mor and
arrow c
rrow-deially 8 weeks later with syngeneic GL261 glioma cells. Any contribution of GFP
ilieu is easily detectable.
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with tumor growth.38,40–42
VEGF, which has been shown to play a critical role in
angiogenesis, also contributes to EPC migration and pro-
liferation. Injection of isolated EPCs in a U87 glioma xe-
nograft model showed that EPCs make up approximately
18% of total vessels, suggesting a significant role for EPCs
in tumor neovascularization. Although the molecular identity
and differentiation lineage of EPCs is debated, these cells
have been defined by their expression of progenitor (CD34,
CD133) and endothelial (CD31, VEGFR-2) markers, as con-
firmed by oligonucleotide microarray analysis of cultured
EPCs from human umbilical cord blood.43
Although vasculogenesis by definition refers to differ-
entiation of EPCs, accumulating evidence suggests that
in addition to bone marrow-derived EPCs, bone marrow-
derived tumor-associated macrophages (TAMs), includ-
ing TIE-2 expressing monocytes (TEMs), circulate in the
blood and home to sites of pathological neovasculariza-
tion and differentiate into endothelial cells or macro-
phages.44,45 The identity of TEMs has been shown as a
subpopulation of tumor-infiltrating CD11b myeloid cells
expressing TIE-2, F4/80, SCA-1 (also known as ataxin-1),
and CD45.46 In mice, the circulating TIE-2CD45 he-
matopoietic cells are mostly CD11bGr-1low/neg, whereas
in humans they express CD14, CD16, and CD11c.45,47
The surface marker profile of mouse and human TEMs is
distinct from the classic profile of inflammatory mono-
cytes and so-called resident monocytes.44,45 Interest-
ingly enough, the vast majority of circulating TEMs lack
expression of EPC markers, such as VEGFR-2, CD133,
CD146, and CD34, but they do express pure hematopoi-
etic markers, such as CD45.46 TEMs are important driv-
ers of tumor angiogenesis and have been found in sev-
eral mouse tumor models, including human GBMs grown
in the mouse brain, and in spontaneous pancreatic tu-
mors developing in RIP1-Tag2 transgenic mice.47
EPCs and TAMs express CXCR4 and migrate in re-
sponse to an SDF-1 gradient.48–50 The importance of
CXCR4/SDF-1 signaling in EPC and TAM mobilization
and recruitment in the setting of central nervous system-
specific malignancies has been emphasized. Consistent
with this pathway, immunoreactivity for SDF-1 is strong
in tumor-associated vessels of GBMs.51,52 SDF-1 pro-
duced by murine gliomas has been shown to contribute
to vasculogenesis by incorporating EPCs into tumor en-
dothelium.53 Moreover, Smadja et al54 found an SDF-1/
CXCR4–mediated increase in EPC migration, whereas
inhibition of SDF-1/CXCR4 signaling inhibited EPC mi-
gration, EPC differentiation, and tubule formation in Matri-
gel, highlighting the role of the SDF-1/CXCR4 axis in
both the migration and differentiation of EPCs.
Like the SDF-1/CXCR4 pathway, the ANG-2/TIE-2
pathway is important for vasculogenesis, and ANG-2 has
been linked to the recruitment of EPCs and TEMs in
tumors.44,55–57 Although some studies suggest a direct
incorporation of BMDCs into tumor vasculature during the
process of vasculogenesis, others point to a more sup-
portive role. Previous animal studies of tumor-associated
vasculogenesis have produced discordant findings, with
possible explanations ranging from insufficient marrow re-constitution, nonoptimized GFP detection based on en-
dogenous fluorescence levels, and undefined time
points. Thus, the exact mechanism of contribution of
EPCs and TEMs to the neovascularization of brain tumors
has yet to be fully elucidated. A transgenic murine glioma
model that can be used to study vasculogenesis is pre-
sented in Figure 3B.
Role of Hypoxia in Vasculogenesis
It is thought that a molecular switch largely induced by
hypoxic conditions also promotes the recruitment of cir-
culating BMDCs, including EPCs and TEMs.47,50,57 For
example, the recruitment and retention of BMDCs into
gliomas has been shown to be, at least in part, controlled
by hypoxia-induced molecular mechanisms, including
the SDF-1/CXCR4 pathway.50,53,58 Moreover, hypoxia
up-regulates TIE-2 expression on TEMs.47,57
Role of Glioma Stem Cells in Vasculogenesis
Folkins et al36 recently described increased microvessel
density and tumor perfusion, as well as mobilization and
homing of EPCs, in tumors rich in cancer stem cells
(CSCs), generated by neurosphere culture, compared
with CSC-poor tumors in the C6 glioma xenograft model.
Moreover, VEGF and SDF-1 were preferentially overex-
pressed by CSC-rich tumor cells in culture. In addition,
blockade of either VEGF or SDF-1 signaling pathways
was sufficient to decrease CSC-rich vascularization to
CSC-poor levels. Finally, endothelial cell proliferation, tu-
bule formation, and EPC mobilization were significantly
decreased with this inhibition. Thus, the molecular mech-
anisms controlling vasculogenesis and leading to the
mobilization and recruitment of EPCs and TEMs to the
neovascularization of brain tumors have been partially
elucidated and appear to be similar, at least in part, to
those described for angiogenesis.
Vascular Mimicry
A fourth mechanism of glioma vascularization, vascular
mimicry, is defined as the ability of tumor cells to form
functional vessel-like networks (Figure 4) and was first
described in human melanoma models. Within tissue
sections of aggressive intraocular and metastatic cuta-
neous melanomas, red blood cell-containing vascular
channel networks were found to be devoid of endothelial
cells. Furthermore, in vitro, invasive and metastatic mela-
noma cells were able to form vascular channels in three
dimensional cultures. Using a three-dimensional culture
and microdissection, Demou and Hendrix59 showed that
networks of aggressive melanoma cells displayed a
strong angiogenic gene expression signature, suggest-
ing an underlying genetic basis for this process.
Evidence for vascular mimicry in gliomas has been
published. Yue and Chen60 demonstrated the presence
of vascular mimicry in 2/45 human astrocytoma samples.
Although endothelium-lined vessels dominated the mi-
crovasculature, a PASCD34 vascular pattern contain-
1132 Hardee and Zagzag
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grade IV. However, the use of PAS as a marker for en-
dothelial cell phenotype is questionable, given that gli-
oma cells also have been described to express PAS.
Shaifer et al61 suggested a link between vascular mim-
icry in GBMs and vascular radioresistance. Using a
three-dimensional organotypic coculture system of GFP-
transfected glioma cells and red vital dye-labeled endo-
thelial cells, they showed that endothelial cells form vas-
cular structures first, followed by incorporation of glioma
cells within 48 hours, creating a mosaic vascular network.
Under angiogenic conditions, glioma cells formed three-
dimensional vascular networks, but characterization of
these glioma cells consistently revealed the absence of
endothelial-specific markers, suggestive of vascular
mimicry. Glioma cells did, however, have reduced ex-pression of glial fibrillary acidic protein (GFAP) and in-
creased expression of CD133, indicating a shift to a stem
cell phenotype. The presence of glioma cells both stabi-
lized vascular structures and conferred vascular radiore-
sistance in vitro. Shaifer et al61 were also able to demon-
strate incorporation of glioma cells into CD31 perfused
vessels in both flank and orthotopic glioma models.
In a study of 101 human glioma samples, Liu et al62
found a correlation between vascular mimicry and World
Health Organization tumor grade. Tumors that contained
evidence of vascular mimicry, defined immunohisto-
chemically as CD34PAS, were more likely to be higher
grade and more aggressive, and these patients had
shorter overall survival times than those without vascular
mimicry. Interestingly enough, tumors exhibiting vascular
Figure 4. Vascular mimicry. A: Vascular mim-
icry is the ability of tumor cells to form func-
tional, perfused, vessel-like networks. These tu-
mor cells lining the vascular channels maintain
glioma morphological characteristics and typical
glioma markers (inset). B: Photomicrographs
demonstrating vascular mimicry. Top row: Low-
and high-power views of H&E-stained sections
of a human GBM demonstrate perfused vascular
networks containing red blood cells (arrows).
Bottom row: Immunohistochemical staining of
this tumor with CD34 (left, immunoperoxidase)
and CD31 (right, immunoperoxidase) reveals
immunoreactive vascular channels different from
those lined by tumor cells and confirms that
these channels are not lined by endothelial cells.
C: Electron micrograph shows tumor cells (black
arrow) lining a vascular channel containing red
blood cells (outlined arrowhead) and poly-
morphonuclear leukocytes (outlined arrow) in
a sectioned human GBM. Scale bar  10 m.
Original magnification: 50 (B, top left, bottom
left, and bottom right); 200 (B, top right).mimicry had lower microvascular densities than those
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complementary neovascularization pathway.
Role of Hypoxia in Vascular Mimicry
Although no evidence exists for a direct relationship be-
tween hypoxia and vascular mimicry in GBMs, Sun et al63
demonstrated that hypoxia influences vascular mimicry in
melanoma models (in which vascular mimicry was first de-
scribed). They showed in hind limb models that hypoxic
tumors (generated by femoral artery ligation) had more ves-
sels containing vascular mimicry than did control tumors
that correlated with HIF-1, VEGF, and MMP levels.
Role of Glioma Stem Cells in Vascular Mimicry
In ubiquitous GFP-transgenic mice with orthotopically in-
jected human GSC-derived tumors, Dong et al64 demon-
strated the incorporation of vascular mimicry in the neo-
vascularization process. They identified the formation of
patterned tubular networks by tumor cells mimicking en-
dothelial-lined vascular networks. Coexpression of HLA
and GFP suggests that cell fusion could be one mecha-
nism by which vascular mimicry occurs.
Chen et al65 studied 48 GBM samples and found non-
endothelial-lined blood vessels in viable regions of the tu-
mor in a majority of tumor sections. CD133 tumor spheres
were generated from GBMs that did or did not exhibit vas-
cular mimicry (VM/VM). In a three-dimensional Matrigel
tube assay, VM cells formed a vasculogenic network
within 2 days and re-exhibited mimicry when reinjected as
xenografts, whereas VM cells did neither.
Using GBM tissue sections, El Hallani et al66 found
both small and large PAS tubular structures containing
red blood cells lined by CD34 cells on the luminal sur-
face. There were also CD34 and CD34 portions within
the same vessel, further suggesting the role of anasto-
mosis in vascular mimicry. CD34 blood vessels lined by
EGFR-amplified cells were identified, implying that the
channels were indeed lined by tumor cells. In CD133
neurosphere cultures of tumors containing tumor-lined
vessels (GSC-A) and tumors containing only endothelial-
lined vessels (GSC-B), GSC-A tumor cells developed a
vascular network in three-dimensional Matrigel culture
within 2 days, whereas GSC-B tumor cells did not. Char-
acterization of GSC-A cells showed overexpression of
multiple factors involved in vasculogenesis, whereas nor-
mal endothelial markers were lacking.
Although there is sufficient evidence to suggest that
vascular mimicry does occur in human GBM (Figure 4, B
and C), the contribution of this mechanism to the overall
neovascularization process on a whole-tumor scale re-
mains unclear. Furthermore, it is very likely that the rela-
tive contribution of vascular mimicry varies widely among
tumors and tumor types, making it more difficult to con-
firm its significance. Nonetheless, the implication (by
Shaifer et al,61 as discussed above) of vascular mimicry
as a complementary neovascularization pathway and its
potential role in radiation resistance makes this novel
mechanism particularly intriguing in a disease such as
GBM, which is characterized by radioresistance.Glioblastoma-Endothelial Cell
Transdifferentiation
The most recently described mechanism of glioma neo-
vascularization involves transdifferentiation of glioma
cells into an endothelial phenotype (Figure 5). As with
vascular mimicry, the hypothesis of endothelial transdif-
ferentiation of tumor cells originated with human cutane-
ous melanoma models. The rather recent identification of
glioma endothelial cell transdifferentiation has yet to be
confirmed, and will need to be further investigated for
complete validation.
Role of Hypoxia in Transdifferentiation
Using an orthotopic model of GFP GBM in GFAP-Cre
recombinase mice, Soda et al67 observed GFP endo-
thelial cells in functional vessels, suggesting a tumor-
derived endothelial cell population. Using GFP tumor
cells in DsRed-transgenic nude mice, they further dem-
onstrated that tumor-derived endothelial cells were not a
result of fusion between tumor cells and endothelial cells.
Similar findings were observed using xenograft tumors of
human GBM spheres and in sections of clinical samples
of GBM tumors that contained von Willebrand factor
(vWF)-positive endothelial cells with EGFR amplifications
characteristic of GBM cells. Reduced oxygen concentra-
tion enhanced this morphological change. tumor-derived
endothelial cells colocalized with hypoxic portions of the
tumor, suggesting a role for hypoxia and HIF-1 in the
transdifferentiation of GBM cells. In vitro, they showed
that growth of GBM cells in endothelial growth medium
induced an endothelial-like phenotype. Despite a signif-
icant induction of VEGF secretion, this process was in-
dependent of VEGF and FGF. Furthermore, treatment
with anti-VEGF therapy in an orthotopic GBM mouse
model had no effect on tumor growth, and significantly
increased the percentage of vessels containing tumor-
derived endothelial cells, compared with control-trea-
ted mice.
Role of Glioma Stem Cells in Transdifferentiation
The close association between endothelial cells and neu-
ral stem cells was demonstrated in a seminal article by
Shen et al,68 who established that factors secreted by
endothelial cells stimulate self-renewal of neural stem
cells and proposed that endothelial cells are an integral
component of the stem cell niche. This vascular niche
has also been applied to GSCs and is the protective
glioma microenvironment, in which GSCs are able to
freely proliferate and remain undifferentiated, completely
unaffected by any external influences.
Ricci-Vitiani et al69 recently demonstrated the process
of endothelial transdifferentiation of GBM stem-like cells.
Using 15 archival GBM specimens, they demonstrated
that a substantial fraction of CD31 endothelial cells ex-
pressed the same chromosomal aberrations as were
present in tumor cells within the specimen, which was
verified in freshly dissociated GBM specimens. Further
staining revealed a subset of GFAP microvascular cells
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that at least some endothelial cells originate from the
tumor itself. The majority of sorted CD31/CD144 GBM
cells expressed vWF. Neurospheres and differentiated
GBM cells were cultured under endothelial conditions,
and only the cells enriched in GSCs generated CD31
and TIE-2 microvascular cultures. In GBM neurosphere
xenografts, 70% of CD31 cells lining functional vessels
from the inner portion of the tumor were of tumor cell
origin. These cells consistently expressed endothelial
markers, but not GSC markers. Lastly, in experiments
using RFP-GBM neurospheres injected in TIE-2-GFP
NOD/SCID mice and confocal microscopy of in vivo an-
giogenesis, GFP mouse vessels were located predom-
inantly outside the tumor.
Another recent study, by Wang et al,70 further demon-
strated the role of GBM stem-like cells in the tumor en-
dothelium. In human GBM specimens, the proportion of
CD105 endothelial cells displaying amplification of
EGFR and of the chromosome 7 centromeric portion was
similar to that of the tumor cells themselves. Dissociated
GBM specimens were then fractionated into groups
based on CD144 and CD133 expression. The angiogenic
endothelial marker CD105 was consistently absent in
CD144/CD133 double-positive populations; however,
when cells were cultured in endothelial medium, CD144
was down-regulated and CD105 and CD31 were up-
regulated with coexpression of VEGFR-2 and CD34. Be-
cause these investigations relied heavily on CD105 as anexclusive endothelial cell marker, evidence indicating
that CD105 can also be expressed by glioma cells71
renders some of the reported observations questionable.
In three-dimensional culture, these CD144/CD133
double-positive-derived endothelial cells formed abnor-
mal vascular networks characteristic of tumor vascula-
ture, leading the authors to postulate that the CD144/
CD133 double-positive population represents the
neoplastic origin of tumor endothelium.70 When cultured
with tumor cells, GFP-labeled CD144/CD133 cells pro-
duced a population of GFP-CD144/CD133 cells that,
when cultured in collagen, formed vacuoles suggestive
of early lumen formation and differentiated into CD105
and CD31 cells. This finding suggests that the CD144/
CD133 double-positive endothelial progenitors within
GBM arise from the CD133 population and can differ-
entiate into an endothelial phenotype. Furthermore, by
performing single-cell clonal studies of CD133/CD144
cells (as well as normal endothelial cells and fibroblasts),
they were able to demonstrate both endothelial and neu-
ral differentiation potential. The authors suggest that the
CD144/CD133 population may represent circulating
EPCs. Transcriptome analysis was also performed and,
although EPCs were found to be highly abnormal, EPCs
were near-diploid, making the possibility of nuclear fusion
as an explanation for these findings highly unlikely.
More recently, Zhao et al72 also described the charac-
teristic flagstone vascular endothelial cell appearance of
Figure 5. Glioblastoma-endothelial cell transdif-
ferentiation. The mechanism of glioma neovas-
cularization involves transdifferentiation of gli-
oma cells into endothelial cells lining vascular
channels (inset), including both a phenotypic
transformation and the expression of typical en-
dothelial-specific markers.glioma stem/progenitor cells (GSPCs) after culture in en-
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of tubular structures when cultured in Matrigel. Further-
more, when stressed by hypoxia or nutrient deprivation,
GSPCs expressed markers of vascular endothelial cells,
including CD31, CD34, and vWF.
Dong et al73 also demonstrated the potential of GSPCs
to transdifferentiate into endothelial cells. Cultures of
GSPCs in transdifferentiation medium resulted in a char-
acteristic flagstone morphology within 10 days, and cul-
ture in Matrigel ultimately produced vessel-like struc-
tures, with some cells appearing as endotheliocytes. The
transdifferentiation process was associated with an in-
crease in transcription and expression levels of markers
of vascular endothelial cells. Orthotopic injection of hu-
man (h) GSPCs into mice produced tumors that con-
tained functional HLA vessels, suggesting that their or-
igin was hGSPCs. Furthermore, examination of clinical
GBM specimens showed relatively high levels of nestin
expression by tumor vessels, as well as tumor cells co-
expressing ABCG2/CD34 or ABCG2/nestin at the intimal
layer of tumor vessels. (ABCG2 is a marker of side pop-
ulation cells.) Dong et al73 speculated that this may rep-
resent interim cells during the transdifferentiation process
from hGSPCs to vascular endothelial cells. This is also
supported by the findings of Shaifer et al,61 who found
that, under proangiogenic conditions, glioma cells did
not acquire endothelial-specific markers, but lost GFAP
expression and gained CD133 expression, indicating a
shift to a more stem/progenitor phenotype.
As the most recently described mechanism of glioma-
associated neovascularization, glioblastoma-endothelial
cell transdifferentiation represents an exciting area of
research. Nonetheless, the relative contribution of this
process to the entire neovascularization process and its
clinical relevance are as yet undefined (much like the
case with vascular mimicry). Although the various reports
discussed above have provided evidence for transdiffer-
entiation in archival GBM specimens, as well as in pre-
clinical and in vitromodels, the use of questionable mark-
ers (such as CD105) and questionable endpoints (such
as flagstone morphology as a surrogate for an endothelial
phenotype) bring into question the validity of some of
these findings.
The demonstration of naturally occurring tumor-spe-
cific mutations in vascular cells [such as isocitrate
dehydrogenase-1 (IDH-1)74] could prove to be useful
in establishing glioblastoma-endothelial cell transdif-
ferentiation as a relevant mechanism in the neovascu-
larization process. Clearly, more work is needed to
confirm this process as significant in glioma-associ-
ated neovascularization.
Targeting Tumor Neovasculature
For decades, tumor neovasculature has been an attrac-
tive target for therapeutic intervention. The rationale for
applying antiangiogenic strategies in malignant brain tu-
mors includes i) the high degree of neovascularization in
high-grade gliomas, ii) avoidance of problems related to
crossing the blood-brain barrier, in contrast to certainchemotherapeutic agents, and iii) normalization of vas-
cular networks leading to synergism with other therapeu-
tic strategies. Antiangiogenic therapy might also repre-
sent a way to target GSCs, thought to be responsible for
the radioresistant and chemoresistant properties exhib-
ited by GBM. Not only are GSCs a source of proangio-
genic factors such as VEGF, but they thrive in the
perivascular niche within the tumor microenvironment
and could possibly be sensitive to therapy directed at
tumor vasculature.75
Several approaches aimed at targeting glioma neovas-
culature have been proposed. High levels of VEGF have
been reported in plasma and tumor fluid in patients with
GBM, and VEGF overexpression has been correlated
with prognosis in GBM.25 Thus, from among the numer-
ous therapeutic targets identified, the VEGF pathway has
been the target of several therapeutic strategies, involv-
ing either VEGF [anti-VEGF monoclonal antibody bevaci-
zumab (Avastin)76 or aflibercept (VEGF Trap)77] or its
receptors.78 To date, by far the most extensive clinical
experience with antiangiogenic therapy in gliomas has
been with bevacizumab. Antiangiogenic therapy with be-
vacizumab has become standard therapy in recurrent
high-grade gliomas in adults. Several clinical trials in
glioma patients have shown that bevacizumab combined
with chemotherapy demonstrates antitumor activity with
acceptable toxicity.79,80 Patients at New York University
Langone Medical Center (and elsewhere) continue to
receive bevacizumab because of i) marked improvement
in quality of life, ii) a demonstrable increase in progres-
sion-free survival compared with historical controls, and
iii) relief from steroid dependence due to diminished tu-
mor edema.80 Beal et al81 reviewed numerous trials using
bevacizumab in recurrent GBM and anaplastic astrocy-
toma, as well as newly diagnosed GBM. As a single
agent in prospective trials of recurrent GBM, bevaci-
zumab has demonstrated a radiographical response rate
of 28% to 35%, a 6-month progression-free survival of
28% to 35%, and median progression-free survival and
overall survival of 3.7 to 4.2 months and 7.2 to 9.2
months, respectively. When combined with chemother-
apy (irinotecan, etoposide, temozolomide, or fotemus-
tine) for recurrent GBM, the radiographical response rate
was higher (35% to 60%), with 6-month progression-free
survival of 37% to 50%. Recent studies have also exam-
ined the feasibility of bevacizumab combined with radia-
tion in the recurrent GBM setting, showing promising
results with acceptable toxicities. The upfront treatment
of newly diagnosed patients with GBM has also been
described, showing improvements in progression-free
survival. Several ongoing trials have reported interim data
on the use of bevacizumab in this setting, with a sugges-
tion of a progression-free survival benefit compared with
historic controls. Although these results are not over-
whelming, they are exciting, given historical radiographi-
cal response rates of 9% and 6-month progression-free
survival of 9% to 15% in similar patients without bevaci-
zumab therapy.81
Aflibercept also targets VEGF. This agent acts as a
decoy receptor for VEGF and has a high affinity for all
isoforms of VEGF-A. In an orthotopic preclinical glioma
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vanced phases of tumor development in reducing tu-
mor burden and increasing survival. Furthermore, the
effect was enhanced in animals treated with prolonged
regimens.77
Failure of Antiangiogenic Therapy
Despite promising response rates with antiangiogenic
therapy, glioma recurrence is common. Commonly seen
after antiangiogenic therapy is a change in vascular phe-
notype at a cellular level, characterized by decreased
microvessel density and normalization in architecture, as
well as altered expression of molecules such as CD34
and fascin.82 Additionally, there have been reports of
altered clinical relapse patterns. For example, we and
others have observed that the pattern of relapse in bev-
acizumab-treated GBM patients is often characterized by
local, as well as distant infiltration of the brain by tumors
that demonstrate increased invasiveness.79,80 This prob-
lem has become more prevalent as the use of bevaci-
zumab has increased in adult glioma patients. Investiga-
tions have been conducted to try to understand why
antiangiogenic therapy may alter tumor biology and pro-
mote, for example, an invasive phenotype.81 Evidence for
similar phenomena after antiangiogenic therapy in other
tumor types has been reported.83 Although metastases
are a rare occurrence in glioma biology, treatment with
antiangiogenic therapy has been shown to increase met-
astatic potential in both breast and melanoma tumors in
preclinical models.84
Experimental evidence suggests that the escape from
antiangiogenic therapy such as bevacizumab is at least
in part linked to four phenotypic/molecular shifts, many of
which are controlled by hypoxia. These include height-
ened invasion, increased vascular co-option, augmented
vasculogenesis, and up-regulation of angiogenic factors
other than VEGF. Several experiments have shown that
antiangiogenic therapy can increase invasion and, in
many cases, vascular co-option.
Rubenstein et al85 showed in an athymic rat model of
GBM that anti-VEGF therapy improved outcomes, but
resulted in increased perivascular tumor infiltration and
vascular co-option evident on histological analysis.
Similarly, treatment with DC101 (an anti-VEGFR-2
monoclonal antibody) in GBM mouse models resulted
in increased tumor invasion and co-option of existing
vasculature.78 Auf et al,86 using a xenograft glioma
model, also showed that inhibition of the inositol-requiring
protein 1 (IRE1), an important sensor of the unfolded
protein response, resulted in both a reduction in the num-
ber of blood vessels and an increase of tumor cell inva-
sion and vascular co-option. Gene expression analysis
revealed a significant decrease in proangiogenic factors
and an increase in proinvasion factors when IRE1 was in-
hibited, consistent with the observed decrease in tumor
vascularity and increase in invasiveness. Using a rat model
of GBM, Sakariassen et al87 showed tumor growth and
up-regulation of proinvasion genes in the absence of angio-
genesis. Of interest, the same observation was made withaflibercept, with resistance leading to increased tumor
growth and increased invasiveness. Vascular co-option has
been observed (as above) in preclinical models. Zuniga et
al88 proposed increased vascular co-option as a mecha-
nism for the observed increase in diffuse relapses seen
after antiangiogenic therapy, although they did not demon-
strate this mechanism pathologically.
Du et al50 demonstrated that VEGF directly inhibits
invasive behavior in vitro, in a Boyden chamber assay.
Lucio-Eterovic et al89 found that immunodepletion of
VEGF resulted in increased MMP expression and inva-
sion of GBM cells in Matrigel. Pàez-Ribes et al90 reported
that decreased VEGF activity resulted in thinner tumor
vasculature and improved survival in a genetically trans-
formed astrocyte murine model of GBM, but was also
associated with dramatic increase in invasive phenotype
of tumor cells. Taken together, these reports confirm that
angiogenesis inhibition and particularly the inhibition of
VEGF is in many cases associated with an increased
invasive phenotype. Thus, clinical strategies of blocking
tumor invasion combined with antiangiogenic therapy
have been proposed.91
Besides increasing invasion and co-option, antiangio-
genic therapy has also been shown to augment vasculo-
genesis. For example, inhibition of VEGF by AZD2171 (a
pan-VEGF tyrosine kinase inhibitor) resulted in an increase
in infiltration of CXCR4 tumor-associated macrophages
and recruitment of endothelial and pericyte progenitor cells
in response to a transient increase in SDF-1.92 The impor-
tance of monitoring vasculogenesis during antiangiogenic
therapy is highlighted by reports that circulating EPCs were
elevated in a subset of patients with gliomas93 and in-
creased with tumor progression after interruption of anti-
VEGF receptor therapy.94 Because no reliable measure of
the biological activity of antiangiogenic agents is yet avail-
able, EPCs have been proposed as potential surrogate
markers. Other biomarkers under consideration include cir-
culating endothelial cells shed by the tumor vasculature,
and plasma levels of SDF-1 and VEGF.
It is also thought that antiangiogenesis may lead to the
up-regulation of other proangiogenic factors, such as
PDGF, PlGF, bFGF, tumor necrosis factor (TNF-), interleu-
kins, neuropilins, and angiogenin. In addition, receptors
such as the hepatocyte growth factor receptor (also known
as proto-oncogene c-Met) and VEGFR-3, are also up-reg-
ulated by antiangiogenesis. Up-regulation of both ligands
and receptors can lead to resistance to antiangiogenic ther-
apies.89,92 Through this mechanism, inhibition of VEGF can
result in a so-called rebound revascularization after discon-
tinuation of anti-VEGF therapy. Similarly, using AZD2171,
Batchelor et al94 demonstrated rapid normalization of gli-
oma vascularization, but with reversibility of this process on
discontinuation or delay in treatment.
Role of Hypoxia in Antiangiogenic Failure
It has been suggested that antiangiogenic therapy leads
to tissue hypoxia95 and may select for hypoxia resistance
in cancer cells.96 In fact, one of the initial responses to
antiangiogenic therapies is an increase in intratumoral
hypoxia.89 Rapisarda et al97 also found that bevaci-
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moral hypoxia and HIF-1-dependent gene expression in
tumor tissue, and Selvakumaran et al98 concluded that
bevacizumab treatment is an effective inducer of a hy-
poxic environment. Pàez-Ribes et al90 reported similar
findings, using both anti-VEGFR-2 and sunitinib treat-
ments. Overexpression of HIF-1 has been correlated
with increased tumor invasiveness and resistance to che-
motherapy.99 More recently, in an intracranial xenograft
model derived from patient tumor neurospheres, Keunen
et al100 found that, although anti-VEGF therapy de-
creased vascular supply to tumors, it also led to a more
hypoxic tumor microenvironment. Subsequent up-regu-
lation of HIF-1 resulted in an increase in tumor cell
invasion. Thus, it seems that inhibiting blood supply
drives the intratumoral accumulation of HIF-1, the Achil-
les’ heel of antiangiogenic therapy.99
Hypoxia also up-regulates factors involved in recruit-
ment of BMDCs, which in turn promote vasculogenesis.
As discussed above, on escape from antiangiogenic
therapy tumors can also display increased vasculogen-
esis. A recent study by Kioi et al58 demonstrated the
importance of vasculogenesis in GBM recurrence and
resistance to radiation therapy. Irradiation of orthotopic
xenografts in mice resulted in a dose-dependent in-
crease in SDF-1/CXCR4 signaling and in entry of
BMDCs (the majority of which were CD11bmyelomono-
cytes) into the tumor. Importantly, inhibition of HIF-1 ab-
rogated the increase in CD11b monocytes recruited tothe tumor and significantly decreased tumor growth. In-
hibition of CXCR4 also prevented the return of blood flow
in irradiated tumors and completely inhibited the recur-
rence of tumors after a single high dose or five daily
doses of radiation. Both CXCR4 inhibition and VEGF in-
hibition decreased the number of endothelial cells in the
tumor after irradiation, but only CXCR4 blockade caused
complete blockage of tumor perfusion. After transplanta-
tion of tumors into irradiated normal tissues to eliminate
local angiogenesis, HIF-1 inhibition or CXCR4 inhibition
completely abrogated tumor growth. In addition, recent
work has shown that both HIF-1 and SDF-1 recruit
CXCR4/MMP-9 BMDCs to the tumor, which in turn pro-
motes recruitment of endothelial and pericyte progenitor
cells.50 Thus, hypoxia appears to be an important mod-
ulating mechanism contributing to the failure of antian-
giogenic therapy.
Role of Other Mechanisms in Antiangiogenic
Failure
We have learned much about the molecular pathways
responsible for the failure of antiangiogenic therapy. On-
going efforts are providing novel scenarios toward further
understanding of the molecular mechanisms associated
with acquisition of resistance to antiangiogenesis. For
example, Soda et al67 recently described an increase in
glioblastoma-endothelial cell transdifferentiation after an-
Figure 6. Mechanisms of glioma-associated
neovascularization. Glioma neovascularization is
a complex and highly regulated process, depen-
dent on the balance of at least five separate path-
ways: A, vascular co-option; B, angiogenesis; C,
vasculogenesis; D, vascular mimicry; and E, glio-
blastoma-endothelial cell transdifferentiation.
These mechanisms are likely intimately con-
nected, with perturbations in one pathway alter-
ing the vascular phenotype. Although there does
appear to be a temporal framework by which
gliomas attain vasculature, it is likely that several
of these processes can and do occur simultane-
ously in different microdomains of the tumor.
BMDCs are shown in blue. N, necrosis.
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another strategy of resistance to antiangiogenic therapy.
Interaction of the Glioma-Associated
Neovascularization Pathways
Through continued investigation, it has become increas-
ingly clear that glioma neovascularization is not a simple
process, but rather a complex and highly regulated one,
dependent on at least five interlinked pathways (Figure 6).
For example, Ricci-Vitiani et al69 proposed that vascular
mimicry and transdifferentiation may be at the ends of a
spectrum, with vascular mimicry representing an incom-
plete transdifferentiation of cancer stem cells toward endo-
thelial phenotype. Indeed, overlap is evident from recent
reports of both vascular mimicry and transdifferentiation. It
also appears that these mechanisms are intimately con-
nected, with perturbations in one pathway shifting the
balance of the remaining pathways and altering the vas-
cular phenotype. As discussed above, several studies
have demonstrated increased vascular co-option, often
associated with heightened invasive phenotype, after an-
tiangiogenic therapy.78,85,86 In addition, vasculogenesis
became the dominant driver of neovascularization in this
setting.58,92
Hypoxia and GSCs each play a critical role in the
molecular events after the modulation of one of the five
pathways of vascularization. For example, Du et al50 and
Kioi et al58 demonstrated that hypoxia-induced HIF-1 in-
creases levels of SDF-1, which in turn recruits CXCR4
BMDCs to tumors, stimulating neovascularization. There
are also significant interactions between the vasculature
and GSC niches within tumors. Seminal work by Shen et
al68 demonstrated a role for endothelial cells in the main-
tenance of neural stem cells, which led to the concept of
the vascular niche. Furthermore, recent reports of trans-
differentiation of cancer stem cells toward an endothelial
phenotype further demonstrated the complexity of glioma
neovascularization.67,69,70,72,73
Although outcomes of antiangiogenic therapy have
been generally encouraging, concerns have emerged
regarding resistance to therapy, rebound revasculariza-
tion, and shifts to a more invasive phenotype. Regard-
less, antiangiogenic therapy is undoubtedly an important
step forward in the development of effective targeted
therapy. It is clear that neovascularization in GBM is more
complex than can be explained by angiogenesis alone.
Furthermore, it is also evident that many of these pro-
cesses occur in tumor types other than glioma. We are
confident that a thorough understanding of the contribut-
ing molecular processes that control the five modalities
we have reviewed should help overcome the treatment
resistance that characterizes gliomas and many other
types of tumors that escape conventional therapies. Us-
ing combinations of therapies (antiangiogenic, antivas-
culogenic, and anti-invasion) represents a logical ap-
proach toward achieving lasting tumor control.Acknowledgments
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